(Q40640983)

22 September 2017

title

Fundamental structure-activity relationships associated with a new structural class of respiratory syncytial virus inhibitor (English)

1 reference

22 September 2017

Kuo Long Yu

1

1 reference

22 September 2017

Yi Zhang

2

1 reference

22 September 2017

Rita L Civiello

3

1 reference

22 September 2017

Kathleen F Kadow

4

1 reference

22 September 2017

Christopher Cianci

5

1 reference

22 September 2017

Mark Krystal

6

1 reference

22 September 2017

Nicholas A Meanwell

7

1 reference

22 September 2017

language of work or name

English

0 references

publication date

1 July 2003

1 reference

22 September 2017

number of pages

4

1 reference

Bioorganic & Medicinal Chemistry Letters

inferred from page(s)

published in

1 reference

22 September 2017

volume

13

1 reference

22 September 2017

issue

13

1 reference

22 September 2017

page(s)

2141-2144

1 reference

Respiratory syncytial virus: recent progress towards the discovery of effective prophylactic and therapeutic agents

22 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

Prevention and treatment recommendations for respiratory syncytial virus infection. Background and clinical experience 40 years after discovery

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

Respiratory syncytial virus (RSV) disease and prospects for its control

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

Continuous non-seasonal epidemic of respiratory syncytial virus infection in the southeast United States.

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

Mortality associated with influenza and respiratory syncytial virus in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

Respiratory syncytial virus infection in immunocompromised adults

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

Biochemistry and clinical applications of ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

An update on respiratory syncytial virus antiviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

Aminodiol HIV protease inhibitors. Synthesis and structure-activity relationships of P1/P1' compounds: correlation between lipophilicity and cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

Aromatic amidines. Comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin, and trypsin

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

Novel and specific respiratory syncytial virus inhibitors that target virus fusion

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

RFI-641 inhibits entry of respiratory syncytial virus via interactions with fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

RSV entry inhibitors block F-protein mediated fusion with model membranes

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

RFI-641, a potent respiratory syncytial virus inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS0960-894X%2803%2900383-4

7 January 2021

10.1016/S0960-894X(03)00383-4

Identifiers

DOI

1 reference

22 September 2017

1 reference